‘Fake news’: Health Ministry on rejecting covid-19 vaccine shot approval

Agencies
December 9, 2020

New Delhi, Dec 9: India's health ministry rejected reports on Wednesday that the country's drugs regulator had declined emergency authorisation for the AstraZeneca Covid-19 vaccine candidate and one developed locally by Bharat Biotech.

Broadcasters NDTV and CNBC-TV18 reported that India's Central Drugs Standard Control Organization (CDSCO) had sought more data from the drugmakers after deliberating on applications made in the past three days.

A source with direct knowledge of the matter told Reuters that a decision on the vaccines would be taken "in toto" and it was too early to say whether they would be rejected or accepted.

India's health ministry denied the reports in a statement on Twitter. The government had said on Tuesday that some vaccines may be approved in the coming weeks.

The Serum Institute of India, which is the local manufacturer of the AstraZeneca vaccine, only applied for emergency approval on Monday.

The SII did not immediately respond to a request for comment. Bharat Biotech declined to comment. The CDSCO did not immediately respond to a request for comment.

NDTV said the CDSCO did not consider a similar application from Pfizer Inc because their US experts could not attend the Wednesday meeting. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Dr Sashikanth Jonnalagadda 
April 14,2021

header-head-neck-cancer.jpg

The Head and Neck is a very complex region of the body and consists of several subsites like the Oral Cavity, Oropharynx (Throat), Larynx (voice box), Thyroid, Paranasal Sinuses, and Neck Lymph Nodes. Cancer that occurs in the Oral Cavity (mouth), throat, nose, paranasal sinuses, salivary glands, and other areas of the head and neck are considered Head and Neck cancer.  
  
Squamous cell carcinomas arise in the lining of the mouth, nose, and throat, account for the majority of these cancers.  
  
Because of the widespread use of Tobacco (gutka, pan masala, and betelnut), oral cancers are the most common form of cancer in India and it accounts for roughly 30 percent of all cancers in the body. Oral Cancers and other Head and Neck Cancers are also increased by smoking and alcohol consumption. 
  
Approximately 20 people out of 1,00,000 population are diagnosed with Head and Neck Cancer.  
  
It is very important to pay attention to symptoms such as non-healing ulcers in the mouth or throat, bleeding from mouth or nose, persisting sore throat, breathing or swallowing difficulty, change in voice, and swellings in the neck and face region. 
  
Head and neck tumors affect the patient's ability to chew, swallow, speak and breathe. As a result, early detection of the tumor is critical in order to increase the patient's chances of survival as well as his or her ability to speak and swallow normally during treatment. 
  
Treatment Options 

These symptoms need to be evaluated with a concerned Head and Neck Onco Surgeons who helps patients to make an informed decision about their treatment options.  The first step is to obtain a tissue sample from the affected area, which is done by a biopsy. The type of cancer will be confirmed by Histopathology, which will decide further management. 
 
The next step is staging, which entails deciding how far cancer has spread. It will be obtained by Radiological Imaging such as CT, MRI, and, on rare occasions PET scan. 
 
Cancers can be classified into four stages based on the extent of their spread. Usually, head and neck cancers are treated with surgery followed by adjuvant treatment such as radiation and chemotherapy, if necessary. The tumor and neck nodes are removed during surgery. Plastic surgery procedures are used to reconstruct the shape and function of the removed organ, allowing the patient to appear and function as normally as possible. 
  
After the treatment, the patient is kept on close surveillance for 3 to 5 years with a follow-up with his or her Head and Neck Surgeon. 

 

By Dr. Sashikanth Jonnalagadda is the Consultant - ENT, Head and Neck Oncology at American Oncology Institute

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
coastaldigest.com news network
April 20,2021

puttur.jpg

Puttur, Apr 20: Two youths met watery graves in Gundia rivulet at Kumbulaya in Noojibalthila of Puttur taluk in Dakshina Kannada yesterday. 

Mohammed Zakir (19), son of Umar from Nellyadi 'Shanthibeettu, and Mohammed Sinaan (21), nephew of Umar from Uppinangady Saralikatte were taking bath in the rivulet when the tragedy took place. 

Zakir was a college student while Sinaan worked in the poultry farm.

The two, who arrived in a motorbike, had ventured into the rivulet from near the bridge. 

Umar called Badruddin sometime later to inform him that his son, Mohammed zakir, and Mohammed Sinan, son of his sister, Asma, had not returned after leaving for Kallugudde at 2 pm for the stated purpose of buying a goat. 

Umar made several calls but the mobile phone was ringing and no one was responding. Badruddin went searching for the two, and during enquiry with some people engaged in fishing in the rivulet, got to know about finding some clothes of men and mobile phones Kumbulaya in Noojibalthila.

With the help of expert divers in the region, a search was conducted deep inside the rivulet, and the bodies were recovered in the evening.

The complainant stated that the family does not have any suspicion of any foul play in these deaths. Kadaba police assistant sub-inspectors Suresh and Chandrashekhar visited the spot. The mortal remains were taken to Kadaba community health centre for post-mortem.

Allegedly, sand extraction takes place at the spot even though the road leading to the rivulet had been closed by the police by digging a trench.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 21,2021

New Delhi, Apr 21: The Serum Institute of India (SII) has announced that it will price its Covishield vaccine at Rs 600 per dose for private hospitals and Rs 400 per dose for state governments.

In a statement, SII has said, "For the next two months, we will address the limited capacity by scaling up the vaccine production. Going ahead, 50% of our capacities will be served to the Government of India's vaccination program, and the remaining 50% of the capacity will be for the state governments and private hospitals."

Comparing the prices with the other vaccines in the world, SII has stated that while American vaccines are priced at Rs 1,500, Russian and Chinese vaccines would cost Rs 750 per dose, making Covishield a cheaper option.

However, the vaccine price will remain at Rs 150 per dose for the Centre.

In an order earlier this week, the Centre said all above 18 years of age are eligible for vaccination from May 1. As it liberalised the vaccination drive, the government allowed states, private hospitals and industrial establishments to procure the vaccine doses directly from manufacturers.

Of the 12.76 crore vaccine doses administered so far, the Covishield comprises over 90% of the vaccine doses, according to government data on Wednesday. Of this, 15 states and union territories have only given Covishield.

Meanwhile, Prime Minister Narendra Modi on Tuesday urged India's vaccine manufacturers to continuously scale up their production capacity to vaccinate all Indians in the shortest possible time. India on Wednesday recorded nearly 3 lakh fresh cases in its biggest jump so far. The death toll has also gone up by over 2,000 in a day.

Interacting with vaccine manufacturers from across the country via video conferencing, PM Modi said the private sector will play an even more active role in the vaccination drive in the coming days and that this will require better coordination between hospitals and the industry.

In another significant move, the Centre has approved advance funds of Rs 3,000 crore for the Serum Institute and Rs 1,500 crore for Bharat Biotech, which is producing the Covaxin shots.

On the other hand, Johnson & Johnson has applied to India's drug regulator seeking permission to conduct phase-3 clinical trial of its single-dose Covid-19 vaccine in India while also seeking an import licence.

They said the company has sought an early meeting of the subject expert committee on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) to take a decision on its application.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.